The DOI matches its Crossref record; 515 of the 515 references it cites were found in a registry or an index.
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2
Abstract
Human CYP1A2 is one of the major CYPs in human liver and metabolizes a number of clinical drugs (e.g., clozapine, tacrine, tizanidine, and theophylline; n > 110), a number of procarcinogens (e.g., benzo[a]pyrene and aromatic amines), and several important endogenous compounds (e.g., steroids). CYP1A2 is subject to reversible and/or irreversible inhibition by a number of drugs, natural substances, and other compounds. The CYP1A gene cluster has been mapped on to chromosome 15q24.1, with close link between CYP1A1 and 1A2 sharing a common 5'-flanking region. The human CYP1A2 gene spans almost 7.8 kb comprising seven exons and six introns and codes a 515-residue protein with a molecular mass of 58,294 Da. The recently resolved CYP1A2 structure has a relatively compact, planar active site cavity that is highly adapted for the size and shape of its substrates. The architecture of the active site of 1A2 is characterized by multiple residues on helices F and I that constitutes two parallel substrate binding platforms on either side of the cavity. A large interindividual variability in the expression and activity of CYP1A2 has been observed, which is largely caused by genetic, epigenetic and environmental factors (e.g., smoking). CYP1A2 is primarily regulated by the aromatic hydrocarbon receptor (AhR) and CYP1A2 is induced through AhR-mediated transactivation following ligand binding and nuclear translocation. Induction or inhibition of CYP1A2 may provide partial explanation for some clinical drug interactions. To date, more than 15 variant alleles and a series of subvariants of the CYP1A2 gene have been identified and some of them have been associated with altered drug clearance and response and disease susceptibility. Further studies are warranted to explore the clinical and toxicological significance of altered CYP1A2 expression and activity caused by genetic, epigenetic, and environmental factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 515
Wang, B., & Zhou, S. F. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709789378198 · Cited by 127
Self-citationRakhit, A. K., Pantze, M. P., Fettner, S. H., Jones, H. M., Charoin, J., Riek, M., Lum, B. L., & Hamilton, M. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0396-z · Cited by 127
Stürmer, E., Moltke, L. L., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12045-7 · Cited by 126
Nonresponse to Clozapine and Ultrarapid CYP1A2 Activity
Eap, C. B., Bender, S., Sirot, E. J., Cucchia, G., Jonzier-Perey, M., Baumann, P., Allorge, D., & Broly, F. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000116646.91923.2f · Cited by 125
Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment
Rostami‐Hodjegan, A., Nurminen, S., Jackson, P. R., & Tucker, G. (1996) · Pharmacogenetics · doi:10.1097/00008571-199604000-00001 · Cited by 125
An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin
Marshall, M. E., Mohler, J. L., Edmonds, K., Williams, B. R., Butler, K. M., Ryles, M., Weiss, L., Urban, D. A., Bueschen, A. J., Markiewicz, M., et al. (1994) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01377124 · Cited by 125
Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation
Corchero, J., Pimprale, S., Kimura, S., & Gonzalez, F. J. (2001) · Pharmacogenetics · doi:10.1097/00008571-200102000-00001 · Cited by 125
Andersson, T., Holmberg, J., Rohss, K. M., & Walan, A. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.t01-1-00702.x · Cited by 125
Kalgutkar, A. S. S., Hang, N. T. T., Vaz, A. D. N., Doan, A., Dalvie, D., McLeod, D., & Murray, J. C. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.10.1240 · Cited by 125
Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation
Zhang, Z., & Kaminsky, L. S. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00120-o · Cited by 124
Petrulis, J. R., Hord, N. G., & Perdew, G. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006873200 · Cited by 124
Orlando, R. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.007 · Cited by 123
Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes
Djordjević, N., Ghotbi, R., Bertilsson, L., Јаnkovic, S., & Aklillu, E. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0438-6 · Cited by 122
Carrillo, J. A., Dahl, M., Svensson, J., Alm, C., Rodríguez, I., & Bertilsson, L. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90134-4 · Cited by 122
Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes
Berthou, F., Guillois, B., Riché, C., Dréano, Y., Jacqz-Aigrain, É., & Beaune, P. H. (1992) · Xenobiotica · doi:10.3109/00498259209053129 · Cited by 122
Rate-Determining Steps in Phenacetin Oxidations by Human Cytochrome P450 1A2 and Selected Mutants
Yun, C., Miller, G. P., & Guengerich, F. P. (2000) · Biochemistry · doi:10.1021/bi000869u · Cited by 121
Vickers, A. E. M., Sinclair, J. R., Zollinger, M., Heitz, F., Glänzel, U., Johanson, L., & Fischer, V. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15022-2 · Cited by 120
Stiborová, M., Frei, E., Wießler, M., & Schmeiser, H. H. (2001) · Chemical Research in Toxicology · doi:10.1021/tx010059z · Cited by 119
Estrogen Metabolism–Related Genes and Breast Cancer Risk: The Multiethnic Cohort Study
Marchand, L. L., Donlon, T. A., Kolonel, L. N., Henderson, B. E., & Wilkens, L. R. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0076 · Cited by 118
Chida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J., & Kamataki, T. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00832.x · Cited by 118
Johnson, A. D., Zhang, Y., Papp, A. C., Pinsonneault, J. K., Lim, J.-E., Saffen, D. W., Dai, Z., Wang, D., & Sadée, W. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283050107 · Cited by 118
Drug Interaction Potential of Soy Extract and Panax Ginseng
Anderson, G. D., Rosito, G., Mohustsy, M. A., & Elmer, G. W. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003253636 · Cited by 118
Wokke, J. H. J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03181-9 · Cited by 117
Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources.
Rotzinger, S., Fang, J., & Baker, G. B. (1998) · PubMed · Cited by 116
Oxidative metabolism and genotoxic potential of major isoflavone phytoestrogens
Kulling, S. E., Lehmann, L., & Metzler, M. (2002) · Journal of Chromatography B · doi:10.1016/s1570-0232(02)00215-5 · Cited by 116
In Vitro Inhibition and Induction of Human Hepatic Cytochrome P450 Enzymes by Modafinil
Robertson, P., DeCory, H. H., Madan, A., & Parkinson, A. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15146-x · Cited by 116
Moltke, L. L., Greenblatt, D. J., Duan, S. X., Schmider, J., Kudchadker, L., Fogelman, S. M., Harmatz, J. S., & Shader, R. I. (1996) · Psychopharmacology · doi:10.1007/s002130050149 · Cited by 115
Piver, B., Berthou, F., Dréano, Y., & Lucas, D. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00420-x · Cited by 115
Lü, P., Schrag, M. L., Slaughter, D. E., Raab, C. E., Shou, M., & Rodrigues, A. D. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1352 · Cited by 114
Langouët, S., Furge, L. L., Kerriguy, N., Nakamura, K., Guillouzo, A., & Guengerich, F. P. (2000) · Chemical Research in Toxicology · doi:10.1021/tx990189w · Cited by 113
Granfors, M. T., Backman, J. T., Laitila, J., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.009 · Cited by 113
Desta, Z., Wu, G. M., Morocho, A. M., & Flockhart, D. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.3.336 · Cited by 113
Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women
Sangrajrang, S., Sato, Y., Sakamoto, H., Ohnami, S., Laird, N. M., Khuhaprema, T., Brennan, P., Boffetta, P., & Yoshida, T. (2009) · International Journal of Cancer · doi:10.1002/ijc.24434 · Cited by 112
Isozyme- and species-specific susceptibility of cDNA-expressed CYP1A P-450s to different flavonoids
Ib, T., Михайленко, В. М., & Gelboin, H. V. (1994) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(94)90252-6 · Cited by 112
Rost, K. L., & Roots, I. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.49 · Cited by 112
CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: A meta-analysis
Shi, X., Zhou, S., Wang, Z., Zhou, Z., & Wang, Z. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.08.004 · Cited by 111
Self-citationLaika, B., Leucht, S., Heres, S., Schneider, H., & Steimer, W. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.32 · Cited by 110
Ueda, R., Iketaki, H., Nagata, K., Kimura, S., Gonzalez, F. J., Kusano, K., Yoshimura, T., & Yamazoe, Y. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.021220 · Cited by 110
Oxidative metabolism of zolpidem by human liver cytochrome P450S.
Pichard‐Garcia, L., Gillet, G., Bonfils, C., Domergue, J., Thénot, J., & Maurel, P. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06824-2 · Cited by 108
Morrison, H. G., Oleksiak, M. F., Cornell, N. W., Sogin, M. L., & Stegeman, J. J. (1995) · Biochemical Journal · doi:10.1042/bj3080097 · Cited by 107
Clinically Significant Interactions with Drugs Used in the Treatment of Tuberculosis
Ww, Y. (2002) · Drug Safety · doi:10.2165/00002018-200225020-00005 · Cited by 107
7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes
Yamazaki, H., Inoue, K., Mimura, M., Oda, Y., Guengerich, F. P., & Shimada, T. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02178-7 · Cited by 107
Sangster, S. A., Caldwell, J., Hutt, A. J., Anthony, A., & Smith, R. L. (1987) · Xenobiotica · doi:10.3109/00498258709167414 · Cited by 107
Qiu, F., Zhang, R., Sun, J., Aa, J., Hao, H., Peng, Y. H., Ai, H., & Wang, G. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021030 · Cited by 107
Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene.
Yun, C., Shimada, T., & Guengerich, F. P. (1992) · PubMed · Cited by 107
Lin, B. C., Sullivan, R., Lee, Y., Moran, S. M., Glover, E. A., & Bradfield, C. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705471200 · Cited by 106
Pharmacokinetics of Clozapine and Risperidone: A Review of Recent Literature
Byerly, M., & DeVane, C. L. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00010 · Cited by 106
Siess, M. H., Leclerc, J., Lavier, M.-C. C., Rat, P., & Suschetet, M. (1995) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1995.1010 · Cited by 106
Nielsen, K. K., Flinois, J.-P., Beaune, P. H., & Brøsen, K. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13120-0 · Cited by 105
Komatsu, T., Yamazaki, H., Shimada, N., Nakajima, M., & Yokoi, T. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13674-4 · Cited by 105
Classification of Cytochrome P450 1A2 Inhibitors and Noninhibitors by Machine Learning Techniques
Poongavanam, V., Taboureau, O., Oostenbrink, C., Vermeulen, N. P. E., Olsen, L., & Jørgensen, F. S. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023507 · Cited by 105
Theophylline metabolism in human liver microsomes: inhibition studies.
Tjia, J., Colbert, J. E., & Back, D. J. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12414-2 · Cited by 104
Madden, S. F., Woolf, T. F., Pool, W. F., & Park, B. K. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90342-t · Cited by 103
Fluvoxamine Reduces the Clozapine Dosage Needed in Refractory Schizophrenic Patients
Lu, M., Lane, H., Chen, K., Jann, M. W., Su, M., & Chang, W. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0809 · Cited by 103
Tassaneeyakul, W., Mohamed, Z., Birkett, D., McManus, M. E., Veronese, M. E., Tukey, R. H., Quattrochi, L. C., Gonzalez, F. J., & Miners, J. O. (1992) · Pharmacogenetics · doi:10.1097/00008571-199208000-00004 · Cited by 103
Grabar, P. B., Rozman, B., Tomšič, M., Šuput, D., Logar, D., & Dolžan, V. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0498-2 · Cited by 102
Hu, M., Krausz, K. W., Chen, J. R., Ge, X., Li, J., Gelboin, H. V., & Gonzalez, F. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.924 · Cited by 102
Furuya, H., Shimizu, T., Hirano, K., Hatano, M., Fujii‐Kuriyama, Y., Raag, R., & Poulos, T. L. (1989) · Biochemistry · doi:10.1021/bi00443a011 · Cited by 102
Ogiso, H., Kagi, N., Matsumoto, E., Nishimoto, M., Arai, R., Shirouzu, M., Mimura, J., Fujii‐Kuriyama, Y., & Yokoyama, S. (2004) · Biochemistry · doi:10.1021/bi048736m · Cited by 101
Parikh, A., Josephy, P. D., & Guengerich, F. P. (1999) · Biochemistry · doi:10.1021/bi990142+ · Cited by 99
Özdemir, V., KALOW, W., Okey, A. B., Lam, M. S. M., Albers, L. J., Reist, C., Fourie, J., Posner, P., Collins, E. J., & Roy, R. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200112000-00011 · Cited by 99
Differential Maintenance of Cytochrome P450 Enzymes in Cultured Precision-Cut Human Liver Slices
Renwick, A. B., Watts, P. S., Edwards, R. J., Barton, P. T., Guyonnet, I., Price, R. J., Tredger, J. M., Pelkonen, O., Boobis, A. R., & Lake, B. G. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12051-2 · Cited by 99
Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes
Sahi, J., Hamilton, G. A., Sinz, M., Barros, S., Huang, S. M., Lesko, L. J., & LeCluyse, E. L. (2000) · Xenobiotica · doi:10.1080/004982500237668 · Cited by 99
Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro
Granfors, M. T., Backman, J. T., Laitila, J., & Neuvonen, P. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02028.x · Cited by 98
Identification of the Cytochromes P450 That Catalyze Coumarin 3,4-Epoxidation and 3-Hydroxylation
Born, S. L., Caudill, D., Fliter, K. L., & Purdon, M. P. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.483 · Cited by 98
Effects of grapefruit juice and smoking on verapamil concentrations in steady state
Fuhr, U., Müller-Peltzer, H., Kern, R., Lopez-Rojas, P., Jünemann, M., Harder, S., & Staib, H. A. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0436-7 · Cited by 97
Li, D., Jiao, L., Li, Y., Doll, M. A., Hein, D. W., Bondy, M. L., Evans, D. B., Wolff, R. A., Lenzi, R., Pisters, P. W. T., et al. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi171 · Cited by 97
Spaldin, V., Madden, S. F., Pool, W. F., Woolf, T. F., & Park, B. K. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04316.x · Cited by 96
Ring, B. J., Eckstein, J. A., Gillespie, J. S., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29631-2 · Cited by 96
The human cytochrome Cyp1A2 gene contains regulatory elements responsive to 3-methylcholanthrene.
Quattrochi, L. C., & Tukey, R. H. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09111-4 · Cited by 96
Update on tizanidine for muscle spasticity and emerging indications
Malanga, G. A., Reiter, R. D., & Garay, E. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.12.2209 · Cited by 95
Koyama, E., Chiba, K., Tani, M., & Ishizaki, T. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36731-x · Cited by 95
Haarmann‐Stemmann, T., Bothe, H., Kohli, A., Sydlik, U., Abel, J., & Fritsche, E. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016253 · Cited by 95
Lee, A. J., Kosh, J. W., Conney, A. H., & Zhu, B. T. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29399-x · Cited by 95
Nakajima, M., Nakamura, S., Tokudome, S., Shimada, N., Yamazaki, H., & Yokoi, T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14947-1 · Cited by 94
Fuhr, U., Strobl, G., Manaut, F., et al. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13599-2 · Cited by 94
Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype
Jiang, Z., Dragin, N., Jorge-Nebert, L. F., Martin, M. V., Guengerich, F. P., Aklillu, E., Ingelman‐Sundberg, M., Hammons, G., Lyn‐Cook, B. D., Kadlubar, F. F., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000204994.99429.46 · Cited by 93
Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2
Han, X., Ouyang, D., Chen, X., Shu, Y., Jiang, C., Tan, Z., & Zhou, H. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01686.x · Cited by 92
Induction of Cytochrome P450 Enzymes in Cultured Precision-Cut Human Liver Slices
Edwards, R. J., Price, R. J., Watts, P. S., Renwick, A. B., Tredger, J. M., Boobis, A. R., & Lake, B. G. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.3.282 · Cited by 92
Clozapine Serum Concentrations are Lower in Smoking than in Non‐Smoking Schizophrenic Patients
Seppälä, N., Leinonen, E. V. J., Lehtonen, M., & Kivistö, K. T. (1999) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1999.tb02016.x · Cited by 92
The arylhydrocarbon receptor repressor (AhRR): structure, expression, and function
Haarmann‐Stemmann, T., & Abel, J. (2006) · Biological Chemistry · doi:10.1515/bc.2006.147 · Cited by 92
Regulation of Dioxin Receptor Function by Omeprazole
Dzeletovic, N., McGuire, J., Daujat‐Chavanieu, M., Tholander, J., Ema, M., Fujii‐Kuriyama, Y., Bergman, J., Maurel, P., & Poellinger, L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.19.12705 · Cited by 92
Wooding, S., Watkins, W. S., Bamshad, M. J., Dunn, D. M., Weiss, R. B., & Jorde, L. B. (2002) · The American Journal of Human Genetics · doi:10.1086/342260 · Cited by 92
Lee, A. J., Kosh, J. W., Conney, A. H., & Zhu, B. T. (2001) · PubMed · Cited by 92
Raaska, K., & Neuvonen, P. J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000192 · Cited by 91
Nakajima, M., Iwanari, M., & Yokoi, T. (2003) · Toxicology Letters · doi:10.1016/s0378-4274(03)00216-9 · Cited by 91
Clinical Pharmacokinetics of Fluvoxamine
Perucca, E., Gatti, G., & Spina, E. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199427030-00002 · Cited by 90
Magnusson, M. O., Dahl, M.-L., Cederberg, J., Karlsson, M., & Sandström, R. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100431 · Cited by 90
An Update on Clinical Drug Interactions with the Herbal Antidepressant St. Johns wort
Zhou, S., & Lai, X. (2008) · Current Drug Metabolism · doi:10.2174/138920008784746391 · Cited by 90
Self-citationHan, X., Ouyang, D., Lu, P., Jiang, C.-H., Shu, Y., Chen, X., Tan, Z.-R., & Zhou, H. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00006 · Cited by 89
In Vitro and In Vivo Evaluations of Cytochrome P450 1A2 Interactions with Duloxetine
Lobo, E. D., Bergstrom, R. F., Reddy, S. R., Quinlan, T., Chappell, J., Hong, Q., Ring, B. J., & Knadler, M. P. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847030-00005 · Cited by 89
Stiborová, M. (2002) · Carcinogenesis · doi:10.1093/carcin/23.4.617 · Cited by 88
Jiang, Z., Dalton, T. P., Li, J., Wang, B., Tsuneoka, Y., Shertzer, H. G., Deka, R., & Nebert, D. W. (2005) · Human Mutation · doi:10.1002/humu.20134 · Cited by 87
Self-citationDistinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole
Pastrakuljic, A., Tang, B. K., Roberts, E. A., & Kalow, W. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00769-1 · Cited by 87
Otake, Y., & Walle, T. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.2.103 · Cited by 87
Murayama, N., Soyama, A., Saito, Y., Nakajima, Y., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Kimura, H., Goto, Y., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055798 · Cited by 86
Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin.
Chun, Y., Ryu, S. Y., Jeong, T. C., & Kim, M. Y. (2001) · PubMed · Cited by 85
Özdemir, V., KALOW, W., Posner, P., Collins, E. J., Kennedy, J. L., Tang, B.-K., Albers, L. J., Reist, C., Roy, R., Walkes, W., et al. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00007 · Cited by 85
Lewis, D. F. V., & Lake, B. G. (1996) · Xenobiotica · doi:10.3109/00498259609046745 · Cited by 85
Skene, D. J., Papagiannidou, E., Hashemi, E., Snelling, J., Lewis, D. F. V., Fernandez, M., & Ioannides, C. (2001) · Journal of Pineal Research · doi:10.1034/j.1600-079x.2001.310408.x · Cited by 85
Meunier, V., Bourrié, M., Julian, B., Marti, E., Guillou, F., Berger, Y., & Fabre, G. (2000) · Xenobiotica · doi:10.1080/004982500406426 · Cited by 83
Olesen, O. V., & Línnet, K. (1997) · PubMed · Cited by 83
Site-directed mutageneses of rat liver cytochrome P-450d: axial ligand and heme incorporation
Shimizu, T., Hirano, K., Takahashi, T., Hatano, M., & Fujii‐Kuriyama, Y. (1988) · Biochemistry · doi:10.1021/bi00411a035 · Cited by 82
CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients
van Troostwijk, L. J. A. E. D., Koopmans, R. P., Vermeulen, H. D. B., & Guchelaar, H. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2003.09.010 · Cited by 82
Chen, S., & Zhou, D. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41713-9 · Cited by 81
Birkett, D., Rees, D. L. P., Andersson, T., Gonzalez, F. J., Miners, J. O., & Veronese, M. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb05707.x · Cited by 81
Virtual Screening and Prediction of Site of Metabolism for Cytochrome P450 1A2 Ligands
Poongavanam, V., Hritz, J., Taboureau, O., Olsen, L., Jørgensen, F. S., Vermeulen, N. P. E., & Oostenbrink, C. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci800371f · Cited by 81
Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma
Obase, Y., Shimoda, T., Kawano, T., Saeki, S., Tomari, S., Mitsuta, K., Matsuse, H., Kinoshita, M., & Kohno, S. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00013-4 · Cited by 81
Levobupivacaine: a new safer long acting local anaesthetic agent
Gristwood, R. W., & Greaves, J. L. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.6.861 · Cited by 80
Single Nucleotide Polymorphisms and Haplotypes of CYP1A2 in a Japanese Population
Soyama, A., Saito, Y., Hanioka, N., Maekawa, K., Komamura, K., Kamakura, S., Kitakaze, M., Tomoike, H., Ueno, K., Goto, Y., et al. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.24 · Cited by 79
Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers
Ghotbi, R., Gomez, A. V., Milani, L. A., Tybring, G., Syvänen, A., Bertilsson, L., Ingelman‐Sundberg, M., & Aklillu, E. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.4 · Cited by 79
Microsomal Binding of Amitriptyline: Effect on Estimation of Enzyme Kinetic Parameters In Vitro
Venkatakrishnan, K., Moltke, L. L., Obach, R. S., & Greenblatt, D. J. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39241-9 · Cited by 79
Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity
Härtter, S., Nordmark, A., Rose, D., Bertilsson, L., Tybring, G., & Laine, K. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01933.x · Cited by 78
Harrison, L., Skinner, S. L., Marbury, T., et al. (2004) · Archives of Dermatological Research · doi:10.1007/s00403-004-0465-4 · Cited by 78
Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2
Zhou, S.-F., Yang, L.-P., Wei, M. Q., Duan, W., & Chan, E. (2009) · Current Drug Metabolism · doi:10.2174/138920009789895552 · Cited by 78
Self-citationOxidation of Ranitidine by Isozymes of Flavin-Containing Monooxygenase and Cytochrome P450
Chung, W., Park, C., Roh, H., Lee, W.-K., & Cha, Y. (2000) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.84.213 · Cited by 78
Involvement of Human CYP1A Isoenzymes in the Metabolism and Drug Interactions of Riluzole In Vitro
Sanderink, G.-J., Bournique, B., Stevens, J. C., Petry, M., & Martinet, M. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36944-7 · Cited by 78
EXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTES
Roymans, D., Annaert, P., Houdt, J. V., Weygers, A., Noukens, J., Sensenhauser, C., Silva, J., Looveren, C. V., Hendrickx, J., Mannens, G., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003046 · Cited by 78
Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2
Buters, J., Tang, B.-K., Pineau, T., Gelboin, H. V., Kimura, S., & Gonzalez, F. J. (1996) · Pharmacogenetics · doi:10.1097/00008571-199608000-00002 · Cited by 77
Single‐ and Multiple‐Dose Pharmacokinetics of Riluzole in White Subjects
Liboux, A. L., Lefebvre, P., Roux, Y. L., Truffinet, P., Aubeneau, M., Kirkesseli, S., & Montay, G. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb05630.x · Cited by 76
Polasek, T. M., Elliot, D. J., Somogyi, A. A., Gillam, E. M. J., Lewis, B. C., & Miners, J. O. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02627.x · Cited by 76
Olesen, O. V., & Línnet, K. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00298.x · Cited by 75
Sarich, T. C., Kalhorn, T. F., Magee, S., Alsayegh, F., Adams, S., Slattery, J. T., Goldstein, J. A., Nelson, S. D., & Wright, J. M. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90148-x · Cited by 75
Identification and Characterization of Human Cytochrome P450 Isoforms Interacting with Pimozide
Desta, Z., Kerbusch, T., Soukhova, N. V., Richard, E., Ko, J.-W., & Flockhart, D. A. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37449-x · Cited by 75
Characterization of the inhibition of P4501A2 by furafylline
Clarke, S. E., Ayrton, A. D., & Chenery, R. J. (1994) · Xenobiotica · doi:10.3109/00498259409043254 · Cited by 74
Chen, Y., Xiao, P., Ouyang, D., Fan, L., Guo, D., Wang, Y., Yang, H., Tu, J., Zhou, G., Huang, Y., et al. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05158.x · Cited by 74
Gunes, A., Özbey, G., Vural, E. H., Uluoğlu, C., Scordo, M. G., Zengil, H., & Dahl, M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.22 · Cited by 74
The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects.
Batty, K. T., Davis, T. M. E., Ilett, K., et al. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04453.x · Cited by 74
Lang, D. H., & Rettie, A. E. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00265.x · Cited by 73
Yoshinari, K., Ueda, R., Kusano, K., Yoshimura, T., Nagata, K., & Yamazoe, Y. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.04.005 · Cited by 73
Functional characterization of four allelic variants of human cytochrome P450 1A2
Zhou, H., Josephy, P. D., Kim, D., & Guengerich, F. P. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.11.019 · Cited by 73
Involvement of CYP1A2 in mexiletine metabolism
Nakajima, M., Kobayashi, K., Shimada, N., et al. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00048.x · Cited by 72
Fang, J., McKay, G., Song, J., et al. (2001) · PubMed · Cited by 72
A Rapid Computational Filter for Cytochrome P450 1A2 Inhibition Potential of Compound Libraries
Chohan, K. K., Paine, S. W., Mistry, J., Barton, P., & Davis, A. M. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm048959a · Cited by 71
Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4
Zhou, S.-F., Chan, E., Li, X., & Huang, M. (2005) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.1.1.3.53600 · Cited by 71
Self-citationKerzee, J. K., & Ramos, K. S. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.1.152 · Cited by 71
Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test
Parker, A. C., Pritchard, P., Preston, T., & Choonara, I. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00684.x · Cited by 70
Phenotype of the Cyp1a1/1a2/1b1(-/-) Triple-Knockout Mouse
Dragin, N., Shi, Z., Madan, R., Karp, C. L., Sartor, M. A., Chen, C., Gonzalez, F. J., & Nebert, D. W. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.045658 · Cited by 70
Oxidative Metabolism of Bupivacaine into Pipecolylxylidine in Humans Is Mainly Catalyzed by CYP3A
Gantenbein, M., Attolini, L., Bruguerolle, B., et al. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15053-2 · Cited by 69
In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Milnacipran
Paris, B. L., Ogilvie, B. W., Scheinkoenig, J. A., Ndikum-Moffor, F. M., Gibson, R., & Parkinson, A. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028274 · Cited by 69
Uroporphyrinogen oxidation catalyzed by reconstituted cytochrome P450IA2
Lambrecht, R. W., Sinclair, P. R., Gorman, N., & Sinclair, J. F. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90717-b · Cited by 68
Liver Deformation in Ahr-Null Mice: Evidence for Aberrant Hepatic Perfusion In Early Development
Harstad, E. B., Guite, C. A., Thomae, T. L., & Bradfield, C. A. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.020107 · Cited by 67
Teo, S. K., Sabourin, P. J., O'Brien, K., Kook, K. A., & Thomas, S. D. (2000) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/(sici)1099-0461(2000)14:3<140::aid-jbt3>3.0.co;2-p · Cited by 67
Shimada, T., Murayama, N., Okada, K., Funae, Y., Yamazaki, H., & Guengerich, F. P. (2007) · Chemical Research in Toxicology · doi:10.1021/tx600299p · Cited by 67
Jeurissen, S. M. F., Bogaards, J. J. P., Boersma, M. G., et al. (2005) · Chemical Research in Toxicology · doi:10.1021/tx050267h · Cited by 67
Kanebratt, K. P., Ekehed, S., Otter, C. A., Lutz, M., McPheat, J., Masimirembwa, C. M., & Andersson, T. B. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8812-5 · Cited by 66
Salonen, J. S., Nyman, L. M., Boobis, A. R., Edwards, R. J., Watts, P. S., Lake, B. G., Price, R. J., Renwick, A. B., Gómez‐Lechón, M. J., Castell, J. V., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.9.1093 · Cited by 66
Identification of a novel splice‐site mutation in the CYP1A2 gene
Allorge, D., Chevalier, D., Lo‐Guidice, J., Cauffiez, C., Suard, F., Baumann, P., Eap, C. B., & Broly, F. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01858.x · Cited by 65
Biological Oxidations and P450 Reactions
Savas, Ü., Carstens, C.-P., & Jefcoate, C. R. E. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0339 · Cited by 65
Lozano, J. J., Pastor, M., Cruciani, G., Gaedt, K., Centeno, N. B., Gago, F., & Sanz, F. (2000) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008164621650 · Cited by 65
Inhibitory effects of antiarrhythmic drugs on phenacetin O‐deethylation catalysed by human CYP1A2
Kobayashi, K., Nakajima, M., Chiba, K., et al. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.t01-1-00692.x · Cited by 64
Pavanello, S., Pulliero, A., Lupi, S., Gregorio, P., & Clonfero, E. (2005) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2005.08.008 · Cited by 64
Chevalier, D., Cauffiez, C., Allorge, D., et al. (2001) · Human Mutation · doi:10.1002/humu.49 · Cited by 64
Yueh, M., Nguyen, N., Famourzadeh, M., Strassburg, C. P., Oda, Y., Guengerich, F. P., & Tukey, R. H. (2001) · Carcinogenesis · doi:10.1093/carcin/22.6.943 · Cited by 64
Stresser, D. M., & Kupfer, D. (1998) · PubMed · Cited by 64
The G−113A polymorphism in affects the caffeine metabolic ratio in a Chinese population
Chen, X., WANG, L., ZHI, L., Zhou, G.-D., WANG, H., ZHANG, X., Hao, B., Zhu, Y., Cheng, Z., & HE, F. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.012 · Cited by 63
Cigarette Abstinence, Nicotine Gum, and Theophylline Disposition
Lee, B. L., BENOWITZ, N. L., & JACOB, P. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-4-553 · Cited by 63
Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin
Wolkenstein, P., Tan, C., Lecoeur, S., Wechsler, J., Garcia-Martin, N., Charue, D., Bagot, M., & Beaune, P. H. (1998) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(98)00021-0 · Cited by 63
Backman, J. T., Granfors, M. T., & Neuvonen, P. J. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0127-x · Cited by 63
Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis
Bruno, R., Vivier, N., Montay, G., Liboux, A. É., Powe, L. K., Delumeau, J.-C., & Rhodes, G. R. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90047-3 · Cited by 63
Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies
Venkatakrishnan, K., Schmider, J., Harmatz, J. S., Ehrenberg, B. L., Moltke, L. L., Graf, J. A., Mertzanis, P., Corbett, K. E., Rodriguez, M. C., Shader, R. I., et al. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122012634 · Cited by 63
Theophylline N-demethylations as probes for P4501A1 and P4501A2.
Sarkar, M. A., & Jackson, B. J. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08424-7 · Cited by 63
Agudo, A., Sala, N., Pera, G., Capellá, G., Berenguer, A., García, N., Palli, D., Boeing, H., Giudice, G. D., Saieva, C., et al. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0072 · Cited by 62
Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide
Gerbal‐Chaloin, S., Pichard‐Garcia, L., Fabre, J., Cunha, A. S., Poellinger, L., Maurel, P., & Daujat‐Chavanieu, M. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.07.007 · Cited by 61
Tugnait, M., Hawes, E. M., McKay, G., Eichelbaum, M. F., & Midha, K. K. (1999) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(99)00006-x · Cited by 61
Role of cDNA-Expressed Human Cytochromes P450 in the Metabolism of Diazepam
Yang, T. J., Shou, M., Korzekwa, K. R., Gonzalez, F. J., Gelboin, H. V., & Yang, S. K. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00558-3 · Cited by 61
Pelkonen, O., Myllynen, P. K., Taavitsainen, P., Boobis, A. R., Watts, P. S., Lake, B. G., Price, R. J., Renwick, A. B., Gómez‐Lechón, M. J., Castell, J. V., et al. (2001) · Xenobiotica · doi:10.1080/00498250110055479 · Cited by 61
The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women
Nordmark, A., Lundgren, S., Ask, B., Granath, F. N., & Rane, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01673.x · Cited by 60
Wójcikowski, J., Pichard‐Garcia, L., Maurel, P., & Daniel, W. A. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705195 · Cited by 60
Effects of Trazodone and Fluoxetine in the Treatment of Major Depression
Maes, M. H. J., Westenberg, H. G. M., Vandoolaeghe, E., Demedts, P., Wauters, A., Neels, H. M., & Meltzer, H. Y. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00004 · Cited by 60
Suzuki, H., Morris, J. S., Li, Y., Doll, M. A., Hein, D. W., Liu, J., Jiao, L., Hassan, M., Day, R. S., Bondy, M. L., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn085 · Cited by 60
Self-citationBackman, J. T., Karjalainen, M. J., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02653.x · Cited by 59
Tissue-specific expression and methylation of the human CYP2E1 gene
Botto, F., Sérée, E., Khyari, S. E., de Sousa, G., Massacrier, A., Placidi, M., Cau, P., Pellet, W., Rahmani, R., & Barra, Y. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90145-7 · Cited by 59
Biotransformation of caffeine by cDNA-expressed human cytochromes P-450
Ha, H. R., Follath, F., Chen, J., & Krähenbühl, S. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/bf00226333 · Cited by 59
Accumulation of caffeine in healthy volunteers treated with furafylline.
Tarrus, E., Camı́, J., Roberts, D., Spickett, R. G. W., Celdrán, E., & Segura, J. (1987) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1987.tb03003.x · Cited by 59
Lewis, D. F. V., Lake, B. G., George, S. G., Dickins, M., Eddershaw, P. J., Tarbit, M. H., Beresford, A. P., Goldfarb, P. S., & Guengerich, F. P. (1999) · Toxicology · doi:10.1016/s0300-483x(99)00098-0 · Cited by 59
Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer
Yuan, J., Chan, K. K. L., Coetzee, G. A., Castelao, J. E., Watson, M. A., Bell, D. A., Wang, R., & Yu, M. C. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn136 · Cited by 59
Dragin, N., Dalton, T. P., Miller, M. L., Shertzer, H. G., & Nebert, D. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601159200 · Cited by 59
Xenobiotic Responsive Element in the 5′-Upstream Region of the Human P-450c Gene1
Kubota, M., Sogawa, K., Kaizu, Y., SAWAYA, T., Watanabe, J. A., Kawajiri, K., Gotoh, O., & Fujii‐Kuriyama, Y. (1991) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a123562 · Cited by 58
Wójcikowski, J., Maurel, P., & Daniel, W. A. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006445 · Cited by 58
Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan
Wild, M. J., McKillop, D., & Butters, C. (1999) · Xenobiotica · doi:10.1080/004982599238290 · Cited by 58
Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status
Hirota, T., Ieiri, I., Takane, H., Maegawa, S., Hosokawa, M., Kobayashi, K., Chiba, K., Nanba, E., Oshimura, M., Satō, T., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh313 · Cited by 58
Urinary Metabolite Profiling Reveals CYP1A2-Mediated Metabolism of NSC686288 (Aminoflavone)
Chen, C., Meng, L., Ma, X., Krausz, K. W., Pommier, Y. G., Idle, J. R., & Gonzalez, F. J. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.105213 · Cited by 58
Shimizu, T., Murakami, Y., & HATANO, M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36832-1 · Cited by 57
Chan, V., Charles, B. G., & Tett, S. E. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02415.x · Cited by 56
Hosoya, T., Harada, N., Mimura, J., Motohashi, H., Takahashi, S., Nakajima, O., Morita, M., Kawauchi, S., Yamamoto, M. P., & Fujii‐Kuriyama, Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.016 · Cited by 56
Goda, R., Nagai, D., Akiyama, Y., et al. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008623 · Cited by 56
Liboux, A. L., Cachia, J., Kirkesseli, S., Gautier, J.-Y., Guimart, C., Montay, G., Peeters, P. A. M., Groen, E. W. J., Jonkman, J. H. G., & Wemer, J. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/009127009903900507 · Cited by 55
Bohets, H., Lavrijsen, K., Hendrickx, J., Houdt, J. V., Genechten, V. V., Verboven, P., Meuldermans, W., & Heykants, J. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703246 · Cited by 55
Méndez, M., Sorkin, L., Rossetti, M. V., Astrin, K. H., Batlle, A. M. D. C., Parera, V. E., Aizencang, G. I., & Desnick, R. J. (1998) · The American Journal of Human Genetics · doi:10.1086/302119 · Cited by 55
Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans*
Becquemont, L., Ragueneau, I., Bot, M. A. L., Riché, C., Funck‐Brentano, C., & Jaillon, P. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90095-3 · Cited by 55
KEMPER, B. W. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.11.030 · Cited by 55
Berecz, R., de la Rubia, A., Dorado, P., Fernández‐Salguero, P. M., Dahl, M., & LLerena, A. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0576-4 · Cited by 54
Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda
Christiansen, L., Bygum, A., Jensen, A., Thomsen, K., Brandrup, F., Hørder, M., & Petersen, N. E. (2000) · Human Genetics · doi:10.1007/s004390000415 · Cited by 53
Ishida, M., Otani, K., Kaneko, S., Ohkubo, T., Osanai, T., Yasui, N., Mihara, K., Higuchi, H., & Sugawara, K. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199510030-00002 · Cited by 53
Souček, P. (1999) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1388 · Cited by 53
Hesse, L. M., Venkatakrishnan, K., Moltke, L. L., et al. (2001) · PubMed · Cited by 53
Lurie, G., Maskarinec, G., Kaaks, R., Stanczyk, F. Z., & Marchand, L. L. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0746 · Cited by 52
The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin
Schwartz, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.112244 · Cited by 52
Ayalogu, E. O., Snelling, J., Lewis, D. F. V., Talwar, S., Clifford, M. N., & Ioannides, C. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(95)00071-b · Cited by 51
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“Due to its relatively high expression in liver, CYP1A2 plays a significant role in the metabolism of several clinically important drugs (Gunes & Dahl, 2008; Zhou et al., 2009).”
BackgroundCornelis, M. C., Monda, K. L., Yu, K., Paynter, N., Azzato, E. M., Bennett, S. N., Berndt, S. I., Boerwinkle, E., Chanock, S., Chatterjee, N., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002033 · Cited by 228
Nordestgaard, A. T., Thomsen, M., & Nordestgaard, B. G. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv083 · Cited by 189
Koonrungsesomboon, N., Khatsri, R., Wongchompoo, P., & Teekachunhatean, S. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-017-0011-3 · Cited by 100
Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice
Guo, Y., Pope, C., Cheng, X., Zhou, H., & Klaassen, C. D. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.08.058 · Cited by 77
“AhR activation and the significant induction of Cyp1a enzyme activity can increase the biotransformation of various procarcinogens and promutagens to carcinogens and mutagens that covalently bind to important functional macromolecules such as DNA, which can result in carcinogenic transformation of cells (Zhou et al.,…”
Background
Metadata
- Authors
- Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J.-P.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2009-12-04
- Volume
- 42
- Issue
- 2
- Pages
- 268-354
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W2042005699
- Cited by
- 262
- References
- 515
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.